Altogether, our study presents a potent and tunable approach to achieve two-layer specificity in tumor targeting, exploiting EpCAM as an extracellular target and Ras as an intracellular target, resulting in exceptional specificity toward Ras-addicted tumor cells, even in the absence of activating mutations. This evidence concerns the gene EPCAM and neoplasm.